



UNIVERSITÀ
DEGLI STUDI
FIRENZE

FLORE

Repository istituzionale dell'Università degli Studi di Firenze

H1-receptor stimulation induces hyperalgesia through activation of the phospholipase C-PKC pathway.

Questa è la Versione finale referata (Post print/Accepted manuscript) della seguente pubblicazione:

Original Citation:

H1-receptor stimulation induces hyperalgesia through activation of the phospholipase C-PKC pathway / Nicoletta Galeotti; Petra Malmberg-Aiello; Alessandro Bartolini; Walter Schunack; Carla Ghelardini. - In: NEUROPHARMACOLOGY. - ISSN 0028-3908. - STAMPA. - 47:(2004), pp. 295-303. [10.1016/j.neuropharm.2004.03.013]

Availability:

The webpage <https://hdl.handle.net/2158/326948> of the repository was last updated on 2016-11-09T11:16:41Z

Published version:

DOI: 10.1016/j.neuropharm.2004.03.013

Terms of use:

Open Access

La pubblicazione è resa disponibile sotto le norme e i termini della licenza di deposito, secondo quanto stabilito dalla Policy per l'accesso aperto dell'Università degli Studi di Firenze (<https://www.sba.unifi.it/upload/policy-oa-2016-1.pdf>)

Publisher copyright claim:

La data sopra indicata si riferisce all'ultimo aggiornamento della scheda del Repository FloRe - The above-mentioned date refers to the last update of the record in the Institutional Repository FloRe

(Article begins on next page)

H₁-receptor stimulation induces hyperalgesia through activation of the phospholipase C-PKC pathway

Nicoletta Galeotti^{a,*}, Petra Malmberg-Aiello^a, Alessandro Bartolini^a,
Walter Schunack^b, Carla Ghelardini^a

^a Department of Preclinical and Clinical Pharmacology, Viale G. Pieraccini 6, I-50139 Florence, Italy

^b Institute of Pharmacy, Free University of Berlin (WS), Konigin-Luise-Straße 2+4, 14195 Berlin, Germany

Received 22 January 2004; received in revised form 24 February 2004; accepted 18 March 2004

Abstract

The supraspinal cellular events involved in H₁-mediated hyperalgesia were investigated in a condition of acute thermal pain by means of the mouse hot-plate test. I.c.v. administration of the phospholipase C (PLC) inhibitors U-73122 and neomycin antagonized the hyperalgesia induced by the selective H₁ agonist FMPH. By contrast, U-73343, an analogue of U-73122 used as negative control, was unable to modify the reduction of the pain threshold induced by FMPH. In mice undergoing treatment with LiCl, which impairs phosphatidylinositol synthesis, or treatment with heparin, an IP₃-receptor antagonist, the hyperalgesia induced by the H₁-receptor agonist remained unchanged. Similarly, pretreatment with D-myo inositol did not alter the H₁-induced hypernociceptive response. Neither i.c.v. pretreatment with TMB-8, a blocker of Ca²⁺ release from intracellular stores, nor pretreatment with thapsigargin, a depletor of Ca²⁺ intracellular stores, prevented the decrease of pain threshold induced by FMPH. On the other hand, i.c.v. pretreatment with the selective protein kinase C (PKC) inhibitors calphostin C and chelerytrine resulted in a dose-dependent prevention of the H₁-receptor agonist-induced hyperalgesia. The administration of PKC activators, such as PMA and PDBu, did not produce any effect on FMPH effect. The pharmacological treatments employed did not produce any behavioral impairment of mice as revealed by the rota-rod and hole-board tests. These results indicate a role for the PLC-PKC pathway in central H₁-induced hyperalgesia in mice. Furthermore, activation of PLC-IP₃ did not appear to play a major role in the modulation of pain perception by H₁-receptor agonists.

© 2004 Elsevier Ltd. All rights reserved.

Keywords: Histamine H₁-receptor; Hyperalgesia; Phospholipase C; Inositol-1,4,5-trisphosphate; Protein kinase C; Ca²⁺

1. Introduction

Histamine is a monoamine neurotransmitter so far known to activate three G-protein coupled receptors, the H₁-, H₂-, and H₃-receptors (Hill et al., 1997). The first two histamine receptor genes cloned were H₁ (Yamashita et al., 1991) and H₂ (Ganz et al., 1991). The identification of the H₃ receptor came nearly a decade later (Lovenberg et al., 1999). A novel histamine receptor subtype, named H₄, has recently been discovered (Oda et al., 2000). The histamine receptors belong to the superfamily of G-protein coupled recep-

tor. H₁ receptors are coupled, via the α subunits of the G_{q/11} family, to phospholipase C, and their activation leads to formation of inositol-1,4,5-trisphosphate (IP₃) and diacylglycerol from phospholipids in the cell membrane; IP₃ cause a rapid release of Ca²⁺ from the endoplasmic reticulum. Diacylglycerol activates protein kinase C, while Ca²⁺ activates Ca²⁺/calmodulin-dependent protein kinases and phospholipase A₂ in the target cell. H₂-receptors are linked, via the α subunits of the G_s family, to the stimulation of adenylyl cyclase and thus to the activation of cyclic AMP-dependent protein kinase in the target cell. H₃ and H₄-receptors are coupled via G_i-proteins to the inhibition of adenylyl cyclase (Hill et al., 1997; Leurs et al., 2002).

A large number of studies have examined the role of the central histamine system in modulating nociception.

* Corresponding author. Department of Pharmacology, University of Florence, Viale G. Pieraccini 6, I-50139 Florence, Italy. Tel.: +39-055-4271312; fax: +39-055-4271280.

E-mail address: nicoletta.galeotti@unifi.it (N. Galeotti).

Whilst peripheral histamine is involved in stimulation of nociceptive fibers, it has emerged that central histamine plays an important role in antinociception (Hough, 1988). Histamine itself has been described to produce an increase of the pain threshold of central origin. When administered into the cerebral ventricles or periaqueductal gray, it has been reported to have antinociceptive effects in various analgesic tests in mice and rats (Glick and Crane, 1978; Chung et al., 1984; Malmberg-Aiello et al., 1994). Subsequently, it has been demonstrated that substances that increase histamine brain levels, such as the precursor L-histidine, the H₃-receptor antagonist thioperamide, and the catabolism inhibitor metoprine, are able to induce antinociception as well (Malmberg-Aiello et al., 1994). Conversely, reductions in brain histamine concentrations by administration of α -fluoromethylhistidine (α -FMH) or H₃-receptor agonist have a pronociceptive action or block the effects of the histamine increasing agents (Malmberg-Aiello et al., 1994, 1997).

However, not only the H₃-receptor subtype, but also the H₂ and H₁-receptors appear to be involved in the modulation of pain perception induced by the histaminergic system. Several evidences indicate that the H₂ subtype is involved in the histamine-mediated antinociception (Brown et al., 2001). An important role in the modulation of pain perception is also played by the H₁-receptor subtype. The H₁-receptor antagonists are widely used as adjuvants in preoperative analgesia as well as in postoperative pain. H₁-receptor antagonists are also able to potentiate opioid analgesia in laboratory animals (Sun et al., 1985). It has also been observed that some antihistamines, such as hydroxyzine, diphenhydramine, pyrilamine and promethazine, are endowed with analgesic properties in both laboratory animals (Rumore and Schlichting, 1985; Sun et al., 1985; Rumore and Schlichting, 1986) and humans (Rumore and Schlichting, 1986). More recently, it has been reported that the activation of H₁-receptors by using selective agonists not only prevents the antinociception induced by H₁-receptor antagonists, but also increases sensitivity to noxious stimuli in rodents (Malmberg-Aiello et al., 1998).

At present, the involvement of the H₁-receptor subtype in pain perception has been documented. However, the intracellular mechanisms responsible for the modulation of pain threshold by H₁-receptors are not elucidated. The aim of the present study was to determine whether the stimulatory effect of H₁-receptor agonists on PLC, and on DAG- and IP₃-mediated intracellular pathways, participates in the mechanism of central hypernociception following activation of the H₁-mediated histaminergic system. To this purpose, 2-(3-trifluoromethylphenyl)histamine (FMPH), a new, potent and selective H₁-receptor agonist (Leschke et al., 1995) was employed.

2. Methods

2.1. Animals

Male Swiss albino mice (24–26 g) from Morini (San Polo d'Enza, Italy) were used. Twelve mice were housed per cage. The cages were placed in the experimental room 24 h before the test for acclimatization. The animals were fed a standard laboratory diet and tap water ad libitum and kept at 22 ± 1 °C with a 12 h light/dark cycle, light on at 7 a.m. All experiments were carried out in accordance with the NIH Guide for the Care and Use of Laboratory animals. All efforts were made to minimize animal suffering, and to reduce the number of animals used.

2.2. Hot-plate test

The method adopted was described by O'Callaghan and Holtzman (1975). Mice were placed inside a stainless steel container, which was set thermostatically at 52.5 ± 0.1 °C in a precision water-bath from KW Mechanical Workshop, Siena, Italy. Reaction times (s), were measured with a stopwatch before and 15, 30, 45 and 60 min after administration of the hyperalgesic drug. The endpoint used was the licking of the fore or hind paws. Those mice scoring less than 12 and more than 18 s in the pretest were rejected (30%). Licking latency values reported in the figures were recorded 15 min after administration of FMPH in correspondence with its maximum effect. Fourteen mice per group were tested.

2.3. Rota-rod test

The apparatus consisted of a base platform and a rotating rod with a diameter of 3 cm and a non-slippery surface. The rod was placed at a height of 15 cm from the base. The rod, 30 cm in length, was divided into five equal sections by six disks. Thus, up to five mice were tested simultaneously on the apparatus, with a rod-rotating speed of 16 r.p.m. The integrity of motor coordination was assessed on the basis of the number of falls from the rod in 30 s according to Vaught et al. (1985). Those mice scoring less than 3 and more than 6 falls in the pretest were rejected (20%). The performance time was measured before (pretest) and 15, 30 and 45 min after the beginning of the test. Ten mice per group were tested.

2.4. Hole-board test

The hole-board test consisted of a 40 cm square plane with 16 flush mounted cylindrical holes (3 cm diameter) distributed 4 by 4 in an equidistant, grid-like manner. Mice were placed on the center of the board one by one and allowed to move about freely for a per-

iod of 5 min each. Two electric eyes, crossing the plane from mid-point to mid-point of opposite sides, thus dividing the plane into four equal quadrants, automatically signaled the movement of the animal (counts in 5 min) on the surface of the plane (spontaneous motility). Miniature photoelectric cells, in each of the 16 holes, recorded (counts in 5 min) the exploration of the holes (exploratory activity) by the mice. Ten mice per group were tested.

2.5. *I.c.v. injection technique*

I.c.v. administration was performed under ether anesthesia with isotonic saline as solvent, according to the method described by Haley and McCormick (1957). During anesthesia, mice were grasped firmly by the loose skin behind the head. A hypodermic needle (0.4 mm external diameter) attached to a 10 μ l syringe was inserted perpendicularly through the skull and no more than 2 mm into the brain of the mouse, where 5 μ l solution was then administered. The injection site was 1 mm to the right or left from the midpoint on a line drawn through to the anterior base of the ears. Injections were performed randomly into the right or left ventricle. To ascertain that solutions were administered exactly into the cerebral ventricle, some mice were injected with 5 μ l of diluted 1:10 India ink and their brains were examined macroscopically after sectioning. The accuracy of the injection technique was evaluated with 95% of injections being correct.

2.6. *Drugs*

The following drugs were used: FMPH (2-(3-trifluoromethylphenyl)histamine dihydrogenmaleate) (Institute of Pharmacy, Freie Universität, Berlin); TMB-8 (8-(*N,N*-diethylamino)-octyl-3,4,5-trimethoxybenzoate) hydrochloride, heparin sodium salt (mol. wt: approx. 60,000), lithium chloride, (Sigma, Milan, Italy); calphostin C, chelerytrine, U-73122 (1-[6-[[17 β -3-methoxyestra-4,3,5(10)-trien-17-yl]amino]hexyl]1*H*-pyrrole-2,5-dione), U-73343 (1-[6-[[17 β -3-methoxyestra-1,3,5(10)-trien-17-yl]amino]hexyl]-1*H*-pyrrolidinedione), neomycin sulphate, phorbol-12,13-dibutyrate (PDBu), phorbol-12-myristate-13-acetate (PMA), thapsigargin, D-myo inositol 1,4,5-trisphosphate hexasodium salt (Calbiochem, Milan, Italy); D-amphetamine (De Angeli, Rome, Italy). Other chemicals were of the highest quality commercially available. U-73122, U-73343, calphostin C, chelerytrine, PMA, PDBu were dissolved in 0.5% DMSO, thapsigargin was dissolved in 30% DMSO, whereas all other drugs were dissolved in isotonic (NaCl 0.9%) saline solution immediately before use. Drug concentrations were prepared so that the necessary dose could be administered in a volume of 5 μ l per mouse by intracerebroventricular (*i.c.v.*) injection

and 10 ml kg^{-1} by subcutaneous (*s.c.*) injection. Thapsigargin was injected 105 min before the test; chelerytrine was injected 90 min before the test; PMA, PDBu, and calphostin C were injected *i.c.v.* 1 h before the test; LiCl was administered *s.c.* 18 h before the test; U-73122, U-73343, TMB-8, heparin, D-myo inositol were injected 15 min before behavioral tests. Doses and administration schedule were chosen on the bases of time-course and dose-response experiments previously performed in our laboratory. Furthermore, literature data confirm the selectivity and efficacy of the above-mentioned treatments at time and concentration used.

2.7. *Statistical analysis*

All experimental results are given as the mean \pm SEM. An analysis of variance ANOVA, followed by Fisher's protected least significant difference procedure for post-hoc comparison were used to verify significance between two means of behavioral results. Data were analyzed with the StatView software for the Macintosh (1992). *P* values of less than 0.05 were considered significant.

3. Results

3.1. *Role of PLC on FMPH-induced hyperalgesia*

The H_1 -receptor agonist FMPH, at the dose of 6.5 μ g per mouse *i.c.v.*, induced hyperalgesia in the mouse hot-plate test which peaked 15 min after administration and then it slowly diminished, disappearing after 60 min (data not shown). The administration of the PLC inhibitor U-73122 (0.6–5.0 μ g per mouse *i.c.v.*) dose-dependently prevented the hypernociception induced by FMPH (6.5 μ g per mouse *i.c.v.*) in the mouse hot-plate test. The U-73122 dose of 0.6 μ g per mouse *i.c.v.* was devoid of any effect, whereas the maximum antagonistic effect was reached at 5.0 μ g per mouse *i.c.v.* By contrast U-73343 (5.0 μ g per mouse *i.c.v.*), an analogue of U-73122 inactive on PLC, used as negative control, did not alter the reduction of pain threshold produced by the H_1 -receptor agonist (Fig. 1A).

The PLC inhibitor neomycin (5–20 μ g per mouse *i.c.v.*) dose-dependently prevented the FMPH hyperalgesic effect, reaching its maximum effect at 10 μ g per mouse *i.c.v.* (Fig. 1B).

U-73122 and neomycin, when injected alone, produced neither an hyperalgesic nor an analgesic effect (Fig. 1A,B).

3.2. *Role of PKC on FMPH-induced hyperalgesia*

Pretreatment with the PKC blocker calphostin C produced a dose-dependent prevention of FMPH-induced (0.6 μ g per mouse *i.c.v.*) hyperalgesia in the




Fig. 1. (A): Prevention by pretreatment with U-73122 (0.6–5 µg per mouse i.c.v.) and lack of effect by U-73343 (5 µg per mouse i.c.v.) of FMPH-induced hyperalgesia. (B): Prevention by pretreatment with neomycin (5–20 µg per mouse i.c.v.) of FMPH-induced hyperalgesia in the mouse hot-plate test. The licking latency values were recorded 15 min after FMPH administration. Vertical lines represent s.e.m. * $P < 0.05$, ** $P < 0.01$ in comparison with saline group. ° $P < 0.05$ in comparison with FMPH-treated group.

mouse hot-plate test. The maximum effect was obtained at the dose of 0.2 µg per mouse i.c.v., whereas the increase of the licking latency values produced by the dose of 0.15 µg per mouse i.c.v. was not statistically significant. The dose of 0.1 µg per mouse i.c.v. was devoid of any effect (Fig. 2). Similarly, pretreatment with chelerytrine (2.5 µg per mouse i.c.v.), another PKC blocker, reverted the hypernociception produced by the H_1 -receptor agonist (Fig. 2). Calphostin C (0.1–0.2 µg per mouse i.c.v.) and chelerytrine (1–2.5 µg per mouse i.c.v.) exerted their antagonistic effect without modifying the mouse pain threshold when administered alone (Fig. 2).

The PKC activators PDBu (1–40 pmol per mouse i.c.v.) and PMA (0.1–15 pmol per mouse i.c.v.) were unable to modify the hyperalgesic effect induced by FMPH (Fig. 3). At the doses employed, the two PKC activators did not modify the animals' licking latency values in comparison with control animals (Fig. 3).




Fig. 2. Prevention by pretreatment with calphostin C (0.1–0.2 µg per mouse i.c.v.) and chelerytrine (1–2.5 µg per mouse i.c.v.) of FMPH (0.6 µg per mouse i.c.v.)-induced hypernociception in the mouse hot-plate test. The licking latency values were recorded 15 min after FMPH administration. Vertical lines represent s.e.m. * $P < 0.05$ in comparison with control group.

3.3. Role of IP_3 on FMPH-induced hyperalgesia

Pretreatment with LiCl (40–200–400 mg kg^{-1} s.c.), which impairs phosphatidylinositol synthesis, 18 h before the test did not prevent the hyperalgesia induced by FMPH (6.5 µg per mouse i.c.v.) in the mouse hot-plate test. The injection of LiCl (400 mg kg^{-1} s.c.) alone, did not modify the licking latency values of mice in comparison with saline-treated animals (Fig. 4A).

Similarly, the administration of heparin (1–40 µg per mouse i.c.v.), an antagonist of IP_3 -receptors, did not prevent the decrease of the pain threshold induced by FMPH (6.5 µg per mouse i.c.v.). Furthermore, pretreatment with D-myo inositol did not produce any




Fig. 3. Lack of effect of PDBu (1–40 pmol per mouse i.c.v.) and PMA (1–15 pmol per mouse i.c.v.) of FMPH (0.6 µg per mouse i.c.v.)-induced hypernociception in the mouse hot-plate test. The licking latency values were recorded 15 min after FMPH administration. Vertical lines represent s.e.m. * $P < 0.05$ in comparison with control group.




Fig. 4. (A) Lack of effect of LiCl (40–400 mg kg⁻¹ s.c.) on FMPH (0.6 µg per mouse i.c.v.)-induced hypernociception. (B) Lack of effect of heparin (1–40 µg per mouse i.c.v.) on FMPH (0.6 µg per mouse i.c.v.)-induced hypernociception. The licking latency values were recorded 15 min after FMPH administration. Vertical lines represent s.e.m. **P* < 0.05, ***P* < 0.01 in comparison with control group.

effect on the H₁-receptor agonist hyperalgesia (Fig. 4B). Both heparin and D-myo inositol, when injected alone, did not alter the mouse pain threshold in comparison with the control group (data not shown).

3.4. Role of intracellular Ca²⁺ on FMPH-induced hyperalgesia

TMB-8 (0.01–1 µg per mouse i.c.v.), a blocker of Ca²⁺ release from intracellular stores, administered 15 min before the beginning of the test, did not antagonize FMPH-induced hyperalgesia in the mouse hot-plate test, as illustrated in Fig. 5A.

Pretreatment with thapsigargin (3–9 nmol per mouse i.c.v.), an inhibitor of Ca²⁺ uptake into the endoplasmic reticulum by inhibiting the sarco-endoplasmic reticulum Ca²⁺-ATPases, was unable to modify the reduction of pain threshold induced by the investigated H₁-receptor agonist (Fig. 5B).




Fig. 5. (A) Lack of effect of TMB-8 (0.01–1.0 µg per mouse i.c.v.) on FMPH hypernociception in the mouse hot-plate test. (B) Lack of effect of thapsigargin (3–9 nmol per mouse i.c.v.) on FMPH hypernociception in the mouse hot-plate test. The licking latency values were recorded 15 min after FMPH administration. Vertical lines represent s.e.m. **P* < 0.05 in comparison with control group.

3.5. Effect of treatments on mouse behavior

The compounds used in the present study, at the highest doses investigated, were tested in order to assess their effect on mouse behavior. Mice pretreated with LiCl (400 mg kg⁻¹ s.c.), TMB-8 (1 µg per mouse i.c.v.), neomycin (20 µg per mouse i.c.v.), heparin (40 µg per mouse i.c.v.), D-myo inositol (1 µg per mouse i.c.v.), U-73122 (5 µg per mouse i.c.v.), U-73343 (5 µg per mouse i.c.v.), calphostin C (0.2 µg per mouse i.c.v.), chelerythrine (2.5 µg per mouse i.c.v.), PMA (15 pmol per mouse i.c.v.), PDBu (40 pmol per mouse i.c.v.), thapsigargin (9 nmol per mouse i.c.v.) were evaluated for motor coordination by use of the rota-rod test, and for spontaneous motility and inspection activity by use of the hole-board test.

The endurance time on the rotating rod, evaluated before and 15, 30 and 45 min after the beginning of the rota-rod test, indicated the lack of any impairment in the motor coordination of animals pretreated with LiCl, TMB-8, neomycin, D-myo inositol, heparin or pretreated with U-73122, U-73343, alphostin C, chelerytrine, PMA, PDBu, thapsigargin in comparison, respectively, with saline (Fig. 6A) or vehicle group (Fig. 6B).

The spontaneous motility (Fig. 7) as well as the inspection activity (data not shown) of mice, expressed




Fig. 6. Lack of effect of intracellular pharmacological modulators on motor coordination in the mouse rota-rod test in comparison with saline (panel A) or vehicle (panel B). Vertical lines represent s.e.m.




Fig. 7. Lack of effect of intracellular pharmacological modulators on spontaneous motility in the mouse hole-board test in comparison with saline or vehicle. Vertical lines represent s.e.m.

as counts in 10 min, was unmodified by the above-mentioned compounds in comparison with the corresponding control group.

4. Discussion

The present study investigated and elucidated the intracellular mechanisms involved in central hyperalgesia induced by H_1 -receptor activation in a condition of acute thermal nociception in normal animals. The importance of the receptor-mediated activation of the PLC–PKC pathway to obtain a decrease of the pain threshold by histamine H_1 -receptor stimulation was demonstrated.

Several PLC inhibitors are currently available. U-73122, an aminosteroid, has been found to be a potent inhibitor of aggregation of human platelets induced by a variety of agonists, and this compound has been further characterized as an inhibitor of G-protein-mediated PLC (Wakdo et al., 1983; Yule et al., 1992). Neomycin has been reported to inhibit hormone-stimulated IP_3 production through the blockade of PLC (Phillippe, 1994). The administration of U-73122 and neomycin dose-dependently prevented the hypernociception induced by 2-(3-trifluoromethylphenyl)-histamine (FMPH), a new, potent and selective H_1 -receptor agonist (Leschke et al., 1995). By contrast, U-73343, a succinimido analogue used as negative control for U-73122 being a weak inhibitor of PLC (Bleasdale et al., 1990; Smith et al., 1990), did not modify the hyperalgesia induced by FMPH. These results are in agreement with a previous study which illustrated the

prevention by U-73122, but not U-73343, of the nociceptive response induced by i.pl. administration of histamine in mice (Ueda and Inoue, 2000). It has been reported that U-73122 and U-73343 bind to the histamine H₁-receptor in the concentration range in which U-73122 acts as an inhibitor of PLC. This effect could compromise both the use of U-73122 to provide evidence that an H₁ agonist action is mediated via PLC and the use of U-73343 as negative control (Hughes et al., 2000). The lack of any antagonistic effect by U-73343 observed in the present study suggests that the prevention of FMPH-induced hyperalgesia by U-73122 is mediated by PLC activation. This hypothesis is also supported by the reversal of FMPH hypernociception produced by neomycin. These results indicate that the stimulation of H₁-receptors by i.c.v. administration of FMPH activates the PLC pathway and provides evidence that PI-specific PLC (PLC β) is involved in the H₁-mediated central hyperalgesia.

PLC isozymes hydrolyze the highly phosphorylated lipid phosphatidylinositol 4,5-bisphosphate generating two intracellular products: DAG, an activator of PKC, and IP₃, a universal calcium-mobilizing second messenger. The involvement of PKC in the mechanisms that underlie the development of acute and persistent pain has been widely reported (Basbaum, 1999; Malmberg, 2000; Zimmermann, 2001; Kamei et al., 2001). In the present study, pretreatment with calphostin C and chelerytrine, selective, potent and membrane-permeable PKC inhibitors (Kobayashi et al., 1989; Herbert et al., 1990), dose-dependently reversed the hyperalgesia induced by the H₁-receptor agonist FMPH. Furthermore, activation of PKC by phorbol esters, such as PMA and PDBu (Nishizuka, 1992), did not modify the decrease of pain threshold induced by FMPH. These data clearly indicate that activation of PKC constitutes a significant pathway involved in the central nociceptive response induced by H₁-receptor agonists. Stimulation of histamine H₁-receptors has been shown to induce the expression of the proto-oncogene *c-fos*, a neural marker of pain (Harris, 1998), in human airway (Panettieri et al., 1990), vascular smooth muscle cells (Satoh et al., 1994), hypothalamic neurons (Kjaer et al., 1994), human T lymphocytes (Kitamura et al., 1996). Recently, it has been reported that the PKC inhibitor Ro-31-8220 was able to inhibit completely the *c-fos* response to histamine in CHO-H1 cells expressing the H₁-receptor (Megson et al., 2001), confirming a role of PKC in mediating the nociceptive response induced by H₁-receptor activation.

In addition to causing the activation of PKC, PLC induces IP₃ formation. To investigate the IP₃-mediated pathway, LiCl, an uncompetitive inhibitor of inositol monophosphatase, which regenerates inositol from inositol monophosphate, was used. The LiCl-induced inhibition depletes inositol and prevents the formation

of IP₃ (Kennedy et al., 1990; Phiel and Klein, 2001). Animals pretreated with LiCl did not show any alteration of the hypernociceptive response to administration of FMPH. The lack of involvement of IP₃ in H₁-induced hyperalgesia was also confirmed by the lack of effect of low molecular weight heparin on FMPH-induced decrease of pain threshold. Heparin is an IP₃-receptor antagonist (Jonas et al., 1997). This compound must be injected into cells or perfused onto permeabilized cells because of its high molecular weight (12,000–13,000 Da) and lack of membrane permeability. Some evidence indicates that the low molecular weight heparin (6000 Da) used in this study is membrane permeable. Perfusion of low molecular weight heparin over a non-permeabilized cerebellar slice preparation attenuated glutamate-stimulated increases in free intracellular Ca²⁺ (Jonas et al., 1997). Present results indicate that IP₃ production does not play a major role in the H₁-mediated hypernociceptive response. IP₃, through the interaction with specific receptors located on the endoplasmic reticulum, causes release of Ca²⁺ from intracellular stores into the cytoplasm (Mignery and Sudhof, 1990; Ferris et al., 1992). Since numerous central and peripheral effects induced by H₁-receptor agonists are mediated through variation of the intracellular Ca²⁺ levels (Hill et al., 1997; Brown et al., 2001), we thought it worthwhile to investigate the role played by the intracellular Ca²⁺ in the mechanism of action of FMPH. To this purpose, TMB-8, an agent that antagonizes the mobilization of Ca²⁺ from intracellular stores (Malagodi and Chiou, 1974), and thapsigargin, an inhibitor of Ca²⁺ uptake into the endoplasmic reticulum by inhibiting the sarco-endoplasmic reticulum Ca²⁺-ATPases (Treiman et al., 1998) were used. Pretreatment with TMB-8, as well as with thapsigargin, did not antagonize the decrease of pain threshold induced by the investigated H₁-receptor agonist suggesting that the release of Ca²⁺ from intracellular stores is not necessary to produce histaminergic hyperalgesia. These results are in agreement with a reference in which the lack of effect of thapsigargin on preventing histamine hyperalgesia was observed (Ueda and Inoue, 2000). However, in the same study, the prevention of histamine hyperalgesia by the i.pl. administration of the IP₃ antagonist xestospongine C was reported. The discrepancy between the literature data and the lack of effect produced by the IP₃ antagonist heparin that we observed might let us hypothesize that the central and peripheral histaminergic nociceptive responses are mediated by different intracellular pathways. Furthermore, it should also be considered that in the study of Ueda and Inoue the activation of the histaminergic system was made by i.pl. administration of histamine and we cannot exclude the involvement of a receptor subtype different from the H₁ subtype able to, directly or indirectly, activate the IP₃-mediated

intracellular pathway. As confirmation of the lack of involvement of the PLC-IP₃ intracellular signaling pathway in the hyperalgesia induced by FMPH, we observed no effect by pretreatment with D-myo inositol 1,4,5-trisphosphate on the reduction of the licking latency produced by the administration of the H₁ agonist.

The lack of effect produced by LiCl, TMB-8, heparin, thapsigargin and D-myo inositol-1,4,5-trisphosphate cannot be imputable to the administration of inactive concentrations. At the highest doses used, LiCl, TMB-8 and heparin were able to prevent analgesia induced by cholinomimetic drugs (Galeotti et al., 2002), μ - and δ -opioid agonists (Ohsawa et al., 1998; Narita et al., 2000), thapsigargin was able to potentiate analgesia induced by δ -opioid agonists (Ohsawa et al., 1998) and nicotine (Damaj et al., 1993), and D-myo inositol-1,4,5-trisphosphate restored opioid analgesia in LiCl-pretreated mice (Narita et al., 2000).

The highest doses used of U-73122, neomycin, LiCl, heparin, TMB-8, thapsigargin, calphostin C, chelerythrine, PMA and PDBu, in the absence of co-administration of FMPH, did not modify the licking latency values of mice in comparison with control groups excluding that the prevention of FMPH hyperalgesic effect originates from antinociceptive properties of the compounds employed.

The receptor-mediated activation of the histaminergic system, as well as the modulation of the intracellular events promoted by H₁ agonists, can induce several side effects. It is known that the PKC activator PMA and PDBu are convulsant (Smith and Meldrum, 1992) and, similarly, LiCl can induce neurological toxicity characterized by tremors, convulsion, ataxia (Kores and Lader, 1997). All the compounds, at the highest active doses employed in the present study, did not cause any detectable modification in mouse gross behavior. At the same doses, all treatments did not impair motor coordination nor modify spontaneous motility nor inspection activity in comparison with control groups excluding that the results obtained were due to animals' altered viability. It should be noted that higher doses of the intracellular modulators could not be investigated since they induced toxicity (tremors, convulsions, etc.) in animals. The induction of toxicity can also be considered as an indication not only of the diffusion of these compounds in the brain, but also of the consequent reaching of key targets by using the administration schedule employed in the present study.

Seen as a whole, our data evidence the role of PLC-PKC, through DAG generation, in the induction of the central nociceptive response by H₁-receptor activation in a condition of acute thermal pain in mice. By contrast, the concomitant activation of the PLC-IP₃ pathway does not appear to play a major role in FMPH hyperalgesia.

Acknowledgements

This work was supported by grants from MIUR.

References

- Basbaum, A.I., 1999. Distinct neurochemical features of acute and persistent pain. *Proceedings of the National Academy of Sciences of the United States of America* 96, 7739–7743.
- Bleasdale, J.E., Thakur, N.R., Gremban, R.S., Bundy, G.L., Fitzpatrick, F.A., Smith, R.J., Bunting, S., 1990. Selective inhibition of receptor-coupled phospholipase C-dependent processes in human platelets and polymorphonuclear neutrophils. *Journal of Pharmacology and Experimental Therapeutics* 255, 756–768.
- Brown, R.E., Stevens, D.R., Haas, H.L., 2001. The physiology of brain histamine. *Progress in Neurobiology* 63, 637–672.
- Chung, Y.H., Miyake, H., Kamei, C., Tasaka, K., 1984. Analgesic effect of histamine induced by intracerebral injection into mice. *Agents Actions* 15, 137–142.
- Damaj, M.I., Welch, S.P., Martin, B.R., 1993. Involvement of calcium and L-type channels in nicotine-induced antinociception. *Journal of Pharmacology and Experimental Therapeutics* 266, 1330–1338.
- Ferris, C.D., Cameron, A.M., Haganir, R.L., Snyder, S.H., 1992. Quantal calcium release by purified reconstituted inositol 1,4,5-trisphosphate receptors. *Nature* 35, 350–352.
- Galeotti, N., Bartolini, A., Ghelardini, C., 2003. The phospholipase C-IP₃ pathway is involved in muscarinic antinociception. *Neuropsychopharmacology* 28, 888–897.
- Ganz, I., Schaffer, M., DelValle, J., Lodsdon, C., Campbell, V., Uhler, M., Yamada, T., 1991. Molecular cloning of a gene encoding the histamine H₂ receptor. *Proceedings of the National Academy of Sciences of the United States of America* 88, 429–433.
- Glick, S.D., Crane, L.A., 1978. Opiate-like and abstinence-like effects of intracerebral histamine administration in rats. *Nature* 273, 547–549.
- Haley, T.J., McCormick, W.G., 1957. Pharmacological effects produced by intracerebral injection of drugs in the conscious mouse. *British Journal of Pharmacology and Chemotherapy* 12, 12–15.
- Harris, J.A., 1998. Using c-fos as a neural marker of pain. *Brain Research Bulletin* 45, 1–8.
- Herbert, J.M., Augereau, J.M., Gleye, J., Maffrand, J.P., 1990. Chelerythrine is a potent and specific inhibitor of protein kinase C. *Biochemical and Biophysical Research Communications* 172, 993–999.
- Hill, S.J., Ganellin, C.R., Timmerman, H., Schwartz, J.C., Shankley, N.P., Young, J.M., Schunack, W., Levi, R., Haas, H.L., 1997. International Union of Pharmacology. XIII. Classification of histamine receptors. *Pharmacological Reviews* 49, 253–278.
- Hough, L.B., 1988. Cellular localization and possible functions for brain histamine: recent progress. *Progress in Neurobiology* 30, 469–505.
- Hughes, S.-A.C.F., Gibson, W.J., Young, J.M., 2000. The interaction of U-73122 with the histamine H₁ receptor: implications for the use of U-73122 in defining H₁ receptor-coupled signaling pathway. *Naunyn-Schmiedeberg's Archives of Pharmacology* 362, 555–558.
- Jonas, S., Sugimori, M., Llinas, R., 1997. Low molecular weight heparin a neuroprotectant? *Annals of the New York Academy of Sciences* 825, 389–393.
- Kamei, J., Mizoguchi, H., Narita, M., Tseng, L.F., 2001. Therapeutic potential of PKC inhibitors in painful diabetic neuropathy. *Expert Opinion on Investigational Drugs* 9, 1653–1664.
- Kennedy, E.D., Xhalliss, R.A., Rangan, C.I., Nahorski, S.R., 1990. Reduced inositol polyphosphate accumulation and inositol supply induced by lithium in stimulated cerebral cortex slices. *The Biochemical Journal* 267, 781–786.

- Kitamura, Y., Arima, T., Kitayama, Y., Nomura, Y., 1996. Regulation of $[Ca^{2+}]_i$ rise activated by doxepin-sensitive H_1 -histamine receptors in Jurkat cells, cloned human T lymphocytes. *General Pharmacology* 27, 285–291.
- Kjaer, A., Larsen, P.J., Knigge, U., Moller, M., Warberg, J., 1994. Histamine stimulates c-fos expression in hypothalamic vasopressin-, oxytocin-, and corticotropin-releasing hormone-containing neurons. *Endocrinology* 134, 482–491.
- Kobayashi, E., Nakano, H., Morimoto, M., Tamaoki, T., 1989. Calphostin C (UCN-1028C), a novel microbial compound, is a highly potent and specific inhibitor of protein kinase C. *Biochemical and Biophysical Research Communications* 159, 548–553.
- Kores, B., Lader, M.H., 1997. Irreversible lithium neurotoxicity: an overview. *Clinical Neuropharmacology* 20, 283–299.
- Leschke, C., Elz, S., Garbatg, M., Schunack, W., 1995. Synthesis and histamine H_1 receptor agonist activity of a series of 2-phenylhistamines, 2-heteroarylhistamines, and analogues. *Journal of Medicinal Chemistry* 38, 1287–1294.
- Leurs, R., Watanabe, T., Timmerman, H., 2002. Histamine receptors are finally “coming out”. *Trends in Pharmacological Sciences* 22, 337–339.
- Lovenberg, T.W., Roland, B.L., Wilson, S.J., Jiang, X., Pyati, J., Huvar, A., Jackson, M.R., Erlander, M.G., 1999. Cloning and functional expression of the human histamine H_3 receptor. *Molecular Pharmacology* 55, 1101–1107.
- Malagodi, M.H., Chiou, C.Y., 1974. Pharmacological evaluation of a new Ca^{++} antagonist, 8-(*N,N*-diethylamino)-octyl-3,4,5-trimethoxybenzoate hydrochloride (TMB-8): studied in smooth muscle. *European Journal of Pharmacology* 27, 25–33.
- Malmberg, A.B., 2000. Protein kinase subtypes involved in injury-induced nociception. *Progress in Brain Research* 129, 51–59.
- Malmberg-Aiello, P., Lamberti, C., Ghelardini, C., Giotti, A., Bartolini, A., 1994. Role of histamine in rodent antinociception. *British Journal of Pharmacology* 111, 1269–1279.
- Malmberg-Aiello, P., Lamberti, C., Ipponi, A., Hanninen, J., Ghelardini, C., Bartolini, A., 1997. Effects of two histamine-*N*-methyltransferase inhibitors, SKF 91488 and BW 301U, in rodent antinociception. *Naunyn-Schmiedeberg's Archives of Pharmacology* 355, 354–360.
- Malmberg-Aiello, P., Lamberti, C., Ipponi, A., Bartolini, A., Schunack, W., 1998. Evidence for hypernociception induction following histamine H_1 receptor activation in rodents. *Life Sciences* 63, 463–476.
- Megson, A.C., Walkes, E.M., Hill, S.J., 2001. Role of protein kinase Calpha in signaling from the histamine H_1 receptor to the nucleus. *Molecular Pharmacology* 59, 1012–1021.
- Mignery, G.A., Sudhof, T.C., 1990. The ligand binding sites and transduction mechanism in the inositol-1,4,5-triphosphate receptor. *EMBO Journal* 9, 3893–3898.
- Narita, M., Ohsawa, M., Mizoguchi, H., Aoki, T., Suzuki, T., Tseng, L.F., 2000. Role of the phosphatidylinositol-specific phospholipase C pathway in delta-opioid receptor-mediated antinociception in the mouse spinal cord. *Neuroscience* 99, 327–331.
- Nishizuka, Y., 1992. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. *Science* 258, 607–614.
- O'Callaghan, J.P., Holtzman, S.G., 1975. Quantification of the analgesic activity of narcotic antagonists by a modified hot-plate procedure. *Journal of Pharmacology and Experimental Therapeutics* 192, 497–505.
- Oda, T., Morikawa, N., Saito, Y., Masuho, Y., Matsumoto, S.-I., 2000. Molecular cloning and characterization of a novel type of histamine receptor preferentially expressed in leukocytes. *Journal of Biological Chemistry* 275, 36781–36786.
- Ohsawa, M., Nagase, H., Kamei, J., 1998. Role of intracellular calcium in modification of mu and delta opioid receptor-mediated antinociception by diabetes in mice. *Journal of Pharmacology and Experimental Therapeutics* 286, 780–787.
- Panettieri, R.A., Yadavish, P.A., Kelly, A.M., Rubinstein, N.A., Kotlikoff, M.I., 1990. Histamine stimulates proliferation of airway smooth muscle and induces c-fos expression. *American Journal of Physiology* 259, L365–L371.
- Phiel, C.J., Klein, P.S., 2001. Molecular targets of lithium action. *Annual Reviews of Pharmacology and Toxicology* 41, 789–813.
- Phillippe, M., 1994. Neomycin inhibition of hormone-stimulated smooth muscle contractions in myometrial tissue. *Biochemical and Biophysical Research Communications* 205, 245–250.
- Rumore, M.M., Schlichting, D.A., 1985. Analgesic effects of antihistaminics. *Life Sciences* 36, 403–406.
- Rumore, M.M., Schlichting, D.A., 1986. Clinical efficacy of antihistaminics as analgesics. *Pain* 25, 7–22.
- Satoh, T., Sugama, K., Matsuo, A., Kato, S., Ito, S., Hatanaka, M., Sasaguri, Y., 1994. Histamine as an activator of cell growth and extracellular matrix reconstruction for human vascular smooth muscle cells. *Atherosclerosis* 110, 53–61.
- Smith, S.E., Meldrum, B.S., 1992. The protein kinase C activators, phorbol 12-myristate,13-acetate and phorbol 12,13-dibutyrate, are convulsant in the pico-nanomolar range in mice. *European Journal of Pharmacology* 213, 133–135.
- Smith, R.J., Sam, L.M., Justen, J.M., Bundy, G.L., Bala, G.A., Bleasdale, J.E., 1990. Receptor-coupled signal transduction in human polymorphonuclear neutrophils: effects of a novel inhibitor of phospholipase C-dependent processes on cell responsiveness. *Journal of Pharmacology and Experimental Therapeutics* 253, 688–697.
- Sun, C.-L.J., Hui, F.W., Hanig, J.P., 1985. Effect of H_1 blockers alone and in combination with morphine to produce antinociception in mice. *Neuropharmacology* 24, 1–4.
- Treiman, M., Caspersen, C., Christensen, S.B., 1998. A tool coming of age: thapsigargin as an inhibitor of sarco-endoplasmic reticulum $Ca(2+)$ -ATPases. *Trends in Pharmacological Sciences* 19, 131–135.
- Ueda, H., Inoue, M., 2002. In vivo signal transduction of nociceptive response by kyotorphin (Tyrosine-Arginine) through $G\alpha_i$ - and inositol trisphosphate-mediated Ca^{2+} influx. *Molecular Pharmacology* 57, 108–115.
- Vaught, J., Pelley, K., Costa, L.G., Sether, P., Enna, S.J., 1985. A comparison of the antinociceptive responses to GABA-receptor agonists THIP and baclofen. *Neuropharmacology* 24, 211–216.
- Wakdo, G.L., Northup, J., Perkins, J.P., Harden, T.K., 1983. Characterization of an altered membrane form of the beta-adrenergic receptor produced during agonist-induced desensitization. *Journal of Biological Chemistry* 258, 13900–13908.
- Yamashita, M., Fukui, H., Sugama, K., Horio, Y., Ito, S., Mizuguchi, H., Wada, H., 1991. Expression cloning of acDNA encoding the bovine histamine H_1 receptor. *Proceedings of the National Academy of Sciences of the United States of America* 88, 11515–11519.
- Yule, D.I., Williams, J.A., 1992. U73122 Ca^{2+} oscillations in response to cholecystokinin and carbachol but not to JMV-180 in rat pancreatic acinar cells. *Journal of Biological Chemistry* 267, 1382–1388.
- Zimmermann, M., 2001. Pathobiology of neuropathic pain. *European Journal of Pharmacology* 429, 23–37.